secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041326
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Q2 2023 cash $273.7M, $85M private placement; clinical data milestones set
-------------------------------------------------------------------------------

- Cash and investments $273.7M as of June 30, 2023; expected to fund operating plan into late 2025.
- Completed $85M private placement with Nextech, EcoR1, Frazier, Venrock, Boxer investors.
- Initial Phase 1b data for ORIC-114 at ESMO Oct 20-24, 2023; ORIC-533 data Q4 2023; ORIC-944 data Q1 2024.
- R&D expenses $18.8M in Q2 2023 vs $13.8M in Q2 2022, increase due to program advancement and personnel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017023041326/0000950170-23-041326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017023041326/oric-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer